Search hospitals
>
North Carolina
>
Chapel Hill
Unc Aids Crs
Claim this profile
Chapel Hill, North Carolina 27514
Global Leader in HIV Infection
Global Leader in Human Immunodeficiency Virus Infection
Conducts research for HIV
Conducts research for AIDS
Conducts research for HIV/AIDS
105 reported clinical trials
1 medical researcher
Summary
Unc Aids Crs is a medical facility located in Chapel Hill, North Carolina. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, HIV, AIDS, HIV/AIDS and other specialties. Unc Aids Crs is involved with conducting 105 clinical trials across 68 conditions. There are 1 research doctors associated with this hospital, such as David A. Wohl, MD.
Area of expertise
HIV Infection
Unc Aids Crs has run 81 trials for HIV Infection. Some of their research focus areas include:
Human Immunodeficiency Virus Infection
Unc Aids Crs has run 73 trials for Human Immunodeficiency Virus Infection. Some of their research focus areas include:
Top PIs
Clinical Trials running at Unc Aids Crs
HIV/AIDS
Frailty
HIV Infection
Age-Related Issues
Weakness
HIV
Antibodies
for HIV Prevention
HVTN 206/HPTN 114 is a randomized, double blind, controlled, phase 2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and neutralization of VRC07-523LS, PGT121.414.LS, and PGDM1400LS broadly neutralizing monoclonal antibodies given intravenously in adult participants without HIV. The hypothesis of the study is that the combination of VRC07-523LS and PGT121.414.LS and PGDM1400LS antibodies when administered via the intravenous (IV) route will be safe and tolerable in adult participants without HIV. The study aims to enroll 200 participants across multiple sites with an estimated total duration of participation of eighteen (18) months.
Recruiting
1 award
Phase 2
2 criteria
Dasatinib + Quercetin
for HIV
This clinical trial is a Phase II study designed to test the safety and effectiveness of a combination of dasatinib and quercetin (D+Q) in improving physical function for people with HIV who are frail or prefrail. The study will involve 80 participants, all aged 50 or older, who have been living with HIV for at least 10 years determined to meet criteria for diagnosis of frail or prefrail and are currently on a stable antiretroviral therapy with viral suppression. Participants will be randomly assigned to one of two groups: one group will receive the D+Q treatment, and the other will receive a placebo. The treatment will be given in six cycles over 12 weeks, with participants taking the medication for two days followed by 12 days without treatment. After the 12-week treatment period, participants will be monitored for another 12 weeks to assess the long-term effects. The study aims to determine if D+Q can improve physical function and other health outcomes in this population. Randomization will be stratified by sex and age to ensure balanced groups.
Recruiting
0 awards
Phase 2
2 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Unc Aids Crs?
Unc Aids Crs is a medical facility located in Chapel Hill, North Carolina. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, HIV, AIDS, HIV/AIDS and other specialties. Unc Aids Crs is involved with conducting 105 clinical trials across 68 conditions. There are 1 research doctors associated with this hospital, such as David A. Wohl, MD.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.